Transdermal carrier
Improved formulations for topical treatment that ensure at least localized transdermal or systemic delivery of an active agent through skin, nails or hair follicles are disclosed.
1. A method for impeding lactic acidosis in an individual, the method comprising:
administering to the individual a topical formulation for transdermal delivery of an active agent, wherein the active agent comprises sodium bicarbonate;
wherein the formulation comprises a penetrant that provides a lecithin at 5%-15% w/w of the formulation, sodium bicarbonate at 20%-40% w/w of the formulation, a poloxamer 407 at 1%-15% w/w of the formulation, and an isopropyl palmitate.
2. The method of claim 1 , wherein the topical formulation further comprises one or more of sodium lauryl sulfate at 0.5%-2.5% w/w of the formulation, benzyl alcohol at 0.5%-20% w/w of the formulation and propylene glycol at about 1%-5% w/w of the formulation.
3. The method of claim 1 , wherein the topical formulation further comprises one or both of ethanol and water.
4. The method of claim 1 , wherein absorption of the active agent is between 10-15 minutes after administering the topical formulation.
5. The method of claim 1 , wherein the topical formulation increases athletic performance by up to 64%.
6. The method of claim 1 , wherein the topical formulation delays acidosis burn in the individual undertaking a form of muscle movement.
7. The method of claim 1 , wherein the topical formulation is applied to the individual prior to muscle exertion.
8. The method of claim 1 , wherein the topical formulation further comprises one or more of an electrolyte and readily metabolized nutrients.
9. The method of claim 1 , wherein the topical formulation further comprises one or more of beta-alanine, L-carnitine, adenosine triphosphate, dextrose, creatine monohydrate, beta-hydroxy-beta-methylbutyrate, branched chain amino acids, glutathione, sodium phosphate and caffeine.
10. The method of claim 1 , wherein the topical formulation is administered to the skin of the individual.
11. A method for impeding lactic acidosis in an individual, the method comprising:
administering to the individual a topical formulation for transdermal delivery of an active agent, wherein the active agent comprises sodium bicarbonate;
wherein the formulation comprises a penetrant that provides a lecithin at 5%-15% w/w of the formulation and sodium bicarbonate at 20% — 40% w/w of the formulation, and
wherein the formulation comprises one or more of an isopropyl palmitate, benzyl alcohol at 0.5%-20% w/w of the formulation, propylene glycol at about 1%-5% w/w of the formulation, poloxamer 407 at 1%-15% w/w of the formulation, and sodium lauryl sulfate at 0.5%-2.5% w/w of the formulation.
12. The method of claim 11 , wherein the topical formulation further comprises one or both of ethanol and water.
13. The method of claim 11 , wherein absorption of the active agent is between 10-15 minutes after administering the topical formulation.
14. The method of claim 11 , wherein the topical formulation increased athletic performance by up to 64%.
15. The method of claim 11 , wherein the topical formulation delays acidosis burn in the individual undertaking a form of muscle movement.
16. The method of claim 11 , wherein the topical formulation is administered to the individual prior to muscle exertion.
17. The method of claim 11 , wherein the topical formulation further comprises one or more of an electrolyte and readily metabolized nutrients.
18. The method of claim 11 , wherein the topical formulation further comprises one or more of beta-alanine, L-carnitine, adenosine triphosphate, dextrose, creatine monohydrate, beta-hydroxy-beta-methylbutyrate, branched chain amino acids, glutathione, sodium phosphate and caffeine.
19. The method of claim 11 , wherein the topical formulation is administered to the skin of the individual.